<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="2">35013105</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>31</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2158-3188</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jan</Month>
              <Day>10</Day>
            </PubDate>
          </JournalIssue>
          <Title>Translational psychiatry</Title>
          <ISOAbbreviation>Transl Psychiatry</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Immunological causes of obsessive-compulsive disorder: is it time for the concept of an "autoimmune OCD" subtype?</ArticleTitle>
        <Pagination>
          <StartPage>5</StartPage>
          <MedlinePgn>5</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">5</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41398-021-01700-4</ELocationID>
        <Abstract>
          <AbstractText>Obsessive-compulsive disorder (OCD) is a highly disabling mental illness that can be divided into frequent primary and rarer organic secondary forms. Its association with secondary autoimmune triggers was introduced through the discovery of Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal infection (PANDAS) and Pediatric Acute onset Neuropsychiatric Syndrome (PANS). Autoimmune encephalitis and systemic autoimmune diseases or other autoimmune brain diseases, such as multiple sclerosis, have also been reported to sometimes present with obsessive-compulsive symptoms (OCS). Subgroups of patients with OCD show elevated proinflammatory cytokines and autoantibodies against targets that include the basal ganglia. In this conceptual review paper, the clinical manifestations, pathophysiological considerations, diagnostic investigations, and treatment approaches of immune-related secondary OCD are summarized. The novel concept of "autoimmune OCD" is proposed for a small subgroup of OCD patients, and clinical signs based on the PANDAS/PANS criteria and from recent experience with autoimmune encephalitis and autoimmune psychosis are suggested. Red flag signs for "autoimmune OCD" could include (sub)acute onset, unusual age of onset, atypical presentation of OCS with neuropsychiatric features (e.g., disproportionate cognitive deficits) or accompanying neurological symptoms (e.g., movement disorders), autonomic dysfunction, treatment resistance, associations of symptom onset with infections such as group A streptococcus, comorbid autoimmune diseases or malignancies. Clinical investigations may also reveal alterations such as increased levels of anti-basal ganglia or dopamine receptor antibodies or inflammatory changes in the basal ganglia in neuroimaging. Based on these red flag signs, the criteria for a possible, probable, and definite autoimmune OCD subtype are proposed.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Endres</LastName>
            <ForeName>Dominique</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0001-7322-1195</Identifier>
            <AffiliationInfo>
              <Affiliation>Section for Experimental Neuropsychiatry, Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. dominique.endres@uniklinik-freiburg.de.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. dominique.endres@uniklinik-freiburg.de.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pollak</LastName>
            <ForeName>Thomas A</ForeName>
            <Initials>TA</Initials>
            <Identifier Source="ORCID">0000-0002-6171-0810</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bechter</LastName>
            <ForeName>Karl</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0003-4371-2932</Identifier>
            <AffiliationInfo>
              <Affiliation>Department for Psychiatry and Psychotherapy II, Ulm University, Bezirkskrankenhaus Günzburg, Günzburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Denzel</LastName>
            <ForeName>Dominik</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pitsch</LastName>
            <ForeName>Karoline</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nickel</LastName>
            <ForeName>Kathrin</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Section for Experimental Neuropsychiatry, Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Runge</LastName>
            <ForeName>Kimon</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0002-0263-4360</Identifier>
            <AffiliationInfo>
              <Affiliation>Section for Experimental Neuropsychiatry, Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pankratz</LastName>
            <ForeName>Benjamin</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Klatzmann</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
            <Identifier Source="ORCID">0000-0002-0054-3422</Identifier>
            <AffiliationInfo>
              <Affiliation>AP-HP, Hôpital Pitié-Salpêtrière, Biotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department (i2B), Paris, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Sorbonne Université, INSERM, Immunology-Immunopathology-Immunotherapy (i3), Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tamouza</LastName>
            <ForeName>Ryad</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0003-3992-9565</Identifier>
            <AffiliationInfo>
              <Affiliation>Univ Paris Est Créteil, INSERM, IMRB, Translational Neuropsychiatry, AP-HP, DMU IMPACT, FHU ADAPT, Fondation FondaMental, Créteil, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mallet</LastName>
            <ForeName>Luc</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0001-8061-1167</Identifier>
            <AffiliationInfo>
              <Affiliation>Univ Paris Est Créteil, INSERM, IMRB, Translational Neuropsychiatry, AP-HP, DMU IMPACT, FHU ADAPT, Fondation FondaMental, Créteil, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leboyer</LastName>
            <ForeName>Marion</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0001-5473-3697</Identifier>
            <AffiliationInfo>
              <Affiliation>Univ Paris Est Créteil, INSERM, IMRB, Translational Neuropsychiatry, AP-HP, DMU IMPACT, FHU ADAPT, Fondation FondaMental, Créteil, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Prüss</LastName>
            <ForeName>Harald</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0002-8283-7976</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Voderholzer</LastName>
            <ForeName>Ulrich</ForeName>
            <Initials>U</Initials>
            <Identifier Source="ORCID">0000-0003-0261-3145</Identifier>
            <AffiliationInfo>
              <Affiliation>Schoen Clinic Roseneck, Prien am Chiemsee, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry and Psychotherapy, University Hospital Munich, Munich, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cunningham</LastName>
            <ForeName>Janet L</ForeName>
            <Initials>JL</Initials>
            <Identifier Source="ORCID">0000-0001-7876-7779</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neuroscience, Psychiatry, Uppsala University, Uppsala, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <CollectiveName>ECNP Network Immuno-NeuroPsychiatry</CollectiveName>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Domschke</LastName>
            <ForeName>Katharina</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centre for Basics in Neuromodulation, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Tebartz van Elst</LastName>
            <ForeName>Ludger</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Section for Experimental Neuropsychiatry, Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Schiele</LastName>
            <ForeName>Miriam A</ForeName>
            <Initials>MA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Transl Psychiatry</MedlineTA>
        <NlmUniqueID>101562664</NlmUniqueID>
        <ISSNLinking>2158-3188</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004660" MajorTopicYN="Y">Encephalitis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009771" MajorTopicYN="Y">Obsessive-Compulsive Disorder</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013290" MajorTopicYN="Y">Streptococcal Infections</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>KD: Steering Committee Neurosciences, Janssen. LTvE: Advisory boards, lectures, or travel grants within the last three years: Roche, Eli Lilly, Janssen-Cilag, Novartis, Shire, UCB, GSK, Servier, Janssen and Cyberonics. The remaining authors declare no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>27</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35013105</ArticleId>
        <ArticleId IdType="pmc">PMC8744027</ArticleId>
        <ArticleId IdType="doi">10.1038/s41398-021-01700-4</ArticleId>
        <ArticleId IdType="pii">10.1038/s41398-021-01700-4</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Abramowitz JS, Taylor S, McKay D. Obsessive-compulsive disorder. Lancet. 2009;374:491–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19665647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry. 2010;15:53–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2797569</ArticleId>
            <ArticleId IdType="pubmed">18725912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adam Y, Meinlschmidt G, Gloster AT, Lieb R. Obsessive-compulsive disorder in the community: 12-month prevalence, comorbidity and impairment. Soc Psychiatry Psychiatr Epidemiol. 2012;47:339–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21287144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Glazier K, Calixte RM, Rothschild R, Pinto A. High rates of OCD symptom misidentification by mental health professionals. Ann Clin Psychiatry. 2013;25:201–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23926575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grant JE. Clinical practice: obsessive-compulsive disorder. N Engl J Med. 2014;371:646–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25119610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stein DJ, Costa D, Lochner C, Miguel EC, Reddy Y, Shavitt RG, et al.  Obsessive-compulsive disorder. Nat Rev Dis Primers. 2019;5:52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7370844</ArticleId>
            <ArticleId IdType="pubmed">31371720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rasmussen SA, Eisen JL. The epidemiology and clinical features of obsessive compulsive disorder. Psychiatr Clin North Am. 1992;15:743–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1461792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anholt GE, Aderka IM, van Balkom AJ, Smit JH, Schruers K, van der Wee NJ, et al.  Age of onset in obsessive-compulsive disorder: admixture analysis with a large sample. Psychol Med. 2014;44:185–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23517651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>American Psychiatric Association; DSM-5 Task Force. Diagnostic and Statistical Manual of Mental Disorders: DSM-5, 5th ed.; American Psychiatric Association: Washington, DC, USA, 2013; 947p.</Citation>
        </Reference>
        <Reference>
          <Citation>Robbins TW, Vaghi MM, Banca P. Obsessive-compulsive disorder: puzzles and prospects. Neuron. 2019;102:27–47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30946823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bandelow B, Baldwin D, Abelli M, Altamura C, Dell'Osso B, Domschke K, et al.  Biological markers for anxiety disorders, OCD and PTSD - a consensus statement. Part I: neuroimaging and genetics. World J Biol Psychiatry. 2016;17:321–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27403679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pauls DL. The genetics of obsessive-compulsive disorder: a review. Dialogues Clin Neurosci. 2010;12:149–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3181951</ArticleId>
            <ArticleId IdType="pubmed">20623920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittenger C, Bloch MH, Williams K. Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. Pharmacol Ther. 2011;132:314–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3205262</ArticleId>
            <ArticleId IdType="pubmed">21963369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schiele MA, Thiel C, Deckert J, Zaudig M, Berberich G, Domschke K. Monoamine oxidase A hypomethylation in obsessive-compulsive disorder: reversibility by successful psychotherapy? Int J Neuropsychopharmacol. 2020;23:319–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7251630</ArticleId>
            <ArticleId IdType="pubmed">32133483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schiele MA, Thiel C, Kollert L, Fürst L, Putschin L, Kehle R, et al.  Oxytocin receptor gene DNA methylation: a biomarker of Treatment response in obsessive-compulsive disorder? Psychother Psychosom. 2020;11:1–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32920561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schiele MA, Thiel C, Weidner M, Endres D, Zaudig M, Berberich G, et al.  Serotonin transporter gene promoter hypomethylation in obsessive-compulsive disorder - Predictor of impaired response to exposure treatment? J Psychiatr Res. 2020;132:18–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33035761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simmler LD, Ozawa T. Neural circuits in goal-directed and habitual behavior: Implications for circuit dysfunction in obsessive-compulsive disorder. Neurochem Int. 2019;129:104464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31078577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salkovskis PM, Forrester E, Richards C. Cognitive-behavioural approach to understanding obsessional thinking. Br J Psychiatry Suppl. 1998;35:53–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9829027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gerentes M, Pelissolo A, Rajagopal K, Tamouza R, Hamdani N. Obsessive-compulsive disorder: autoimmunity and neuroinflammation. Curr Psychiatry Rep. 2019;21:78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31367805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Real E, Labad J, Alonso P, Segalàs C, Jiménez-Murcia S, Bueno B, et al.  Stressful life events at onset of obsessive-compulsive disorder are associated with a distinct clinical pattern. Depress Anxiety. 2011;28:367–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21308889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Oudheusden L, Eikelenboom M, van Megen H, Visser H, Schruers K, Hendriks GJ, et al.  Chronic obsessive–compulsive disorder: prognostic factors. Psychol Med. 2018;48:2213–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29310732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skapinakis P, Caldwell DM, Hollingworth W, Bryden P, Fineberg NA, Salkovskis P, et al.  Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2016;3:730–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4967667</ArticleId>
            <ArticleId IdType="pubmed">27318812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirschtritt ME, Bloch MH, Mathews CA. Obsessive-compulsive disorder: advances in diagnosis and treatment. JAMA. 2017;317:1358–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28384832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>da Rocha FF, Correa H, Teixeira AL. Obsessive-compulsive disorder and immunology: a review. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1139–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18262706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marazziti D, Mucci F, Fontenelle LF. Immune system and obsessive-compulsive disorder. Psychoneuroendocrinology. 2018;93:39–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29689421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lamothe H, Baleyte JM, Smith P, Pelissolo A, Mallet L. Individualized immunological data for precise classification of OCD patients. Brain Sci. 2018;8:149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6119917</ArticleId>
            <ArticleId IdType="pubmed">30096863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swedo SE. Sydenham’s chorea. A model for childhood autoimmune neuropsychiatric disorders. JAMA. 1994;272:1788–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7661914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swedo SE, Leonard HL, Mittleman BB, Allen AJ, Rapoport JL, Dow SP, et al.  Identification of children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections by a marker associated with rheumatic fever. Am J Psychiatry. 1997;154:110–2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8988969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swedo SE, Leonard HL, Garvey M, Mittleman B, Allen AJ, Perlmutter S, et al.  Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry. 1998;155:264–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9464208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hyman SE. PANDAS: too narrow a view of the neuroimmune landscape. Am J Psychiatry. 2021;178:5–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33384008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bechter K. The challenge of assessing mild neuroinflammation in severe mental disorders. Front Psychiatry. 2020;11:773.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7469926</ArticleId>
            <ArticleId IdType="pubmed">32973573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orlovska S, Vestergaard CH, Bech BH, Nordentoft M, Vestergaard M, Benros ME. Association of Streptococcal throat infection with mental disorders: testing key aspects of the PANDAS hypothesis in a nationwide study. JAMA Psychiatry. 2017;74:740–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5710247</ArticleId>
            <ArticleId IdType="pubmed">28538981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Westwell-Roper C, Williams KA, Samuels J, Bienvenu OJ, Cullen B, Goes FS, et al.  Immune-related comorbidities in childhood-onset obsessive compulsive disorder: lifetime prevalence in the obsessive compulsive disorder collaborative genetics association study. J Child Adolesc Psychopharmacol. 2019;29:615–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6786333</ArticleId>
            <ArticleId IdType="pubmed">31170001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang K, Frankovich J, Cooperstock M, Cunningham MW, Latimer ME, Murphy TK, et al.  PANS Collaborative Consortium. Clinical evaluation of youth with pediatric acute-onset neuropsychiatric syndrome (PANS): recommendations from the 2013 PANS Consensus Conference. J Child Adolesc Psychopharmacol. 2015;25:3–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4340805</ArticleId>
            <ArticleId IdType="pubmed">25325534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pallanti S, Grassi E, Makris N, Gasic GP, Hollander E. Neurocovid-19: a clinical neuroscience-based approach to reduce SARS-CoV-2 related mental health sequelae. J Psychiatr Res. 2020;130:215–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7428715</ArticleId>
            <ArticleId IdType="pubmed">32836010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steardo L, Jr, Steardo L, Verkhratsky A. Psychiatric face of COVID-19. Transl Psychiatry. 2020;10:261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7391235</ArticleId>
            <ArticleId IdType="pubmed">32732883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franke C, Ferse C, Kreye J, Reincke SM, Sanchez-Sendin E, Rocco A, et al.  High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. Brain Behav Immun. 2020;23:S0889.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7834471</ArticleId>
            <ArticleId IdType="pubmed">33359380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scheid R, Voltz R, Guthke T, Bauer J, Sammler D, von Cramon DY. Neuropsychiatric findings in anti-Ma2-positive paraneoplastic limbic encephalitis. Neurology. 2003;61:1159–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14581698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pettingill P, Kramer HB, Coebergh JA, Pettingill R, Maxwell S, Nibber A, et al.  Antibodies to GABAA receptor α1 and γ2 subunits: clinical and serologic characterization. Neurology. 2015;84:1233–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4366091</ArticleId>
            <ArticleId IdType="pubmed">25636713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Diwani A, Handel A, Townsend L, Pollak T, Leite MI, Harrison PJ, et al.  The psychopathology of NMDAR-antibody encephalitis in adults: a systematic review and phenotypic analysis of individual patient data. Lancet Psychiatry. 2019;6:235–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6384244</ArticleId>
            <ArticleId IdType="pubmed">30765329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cainelli E, Nosadini M, Sartori S, Suppiej A. Neuropsychological and psychopathological profile of anti-Nmdar encephalitis: a possible pathophysiological model for pediatric neuropsychiatric disorders. Arch Clin Neuropsychol. 2019;34:1309–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30418503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Endres D, Maier V, Leypoldt F, Wandinger KP, Lennox B, Pollak TA, et al.  Autoantibody-associated psychiatric syndromes: a systematic literature review resulting in 145 cases. Psychol Med. 2020;7:1–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32892761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foroughipour M, Behdani F, Hebrani P, Marvast MN, Esmatinia F, Akhavanrezayat A. Frequency of obsessive-compulsive disorder in patients with multiple sclerosis: a cross-sectional study. J Res Med Sci. 2012;17:248–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3527042</ArticleId>
            <ArticleId IdType="pubmed">23267376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pérez-Vigil A, Fernández de la Cruz L, Brander G, Isomura K, Gromark C, Mataix-Cols D. The link between autoimmune diseases and obsessive-compulsive and tic disorders: a systematic review. Neurosci Biobehav Rev. 2016;71:542–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27687817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ong LTC, Galambos G, Brown DA. Primary Sjogren’s syndrome associated with treatment-resistant obsessive-compulsive disorder. Front Psychiatry. 2017;8:124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5504162</ArticleId>
            <ArticleId IdType="pubmed">28744230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lüngen EM, Maier V, Venhoff N, Salzer U, Dersch R, Berger B, et al.  Systemic lupus erythematosus with isolated psychiatric symptoms and antinuclear antibody detection in the cerebrospinal fluid. Front Psychiatry. 2019;10:226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6494960</ArticleId>
            <ArticleId IdType="pubmed">31105597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mataix-Cols D, Frans E, Pérez-Vigil A, Kuja-Halkola R, Gromark C, Isomura K, et al.  A total-population multigenerational family clustering study of autoimmune diseases in obsessive-compulsive disorder and Tourette’s/chronic tic disorders. Mol Psychiatry. 2018;23:1652–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5951741</ArticleId>
            <ArticleId IdType="pubmed">29133949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang LY, Chen SF, Chiang JH, Hsu CY, Shen YC. Systemic autoimmune diseases are associated with an increased risk of obsessive-compulsive disorder: a nationwide population-based cohort study. Soc Psychiatry Psychiatr Epidemiol. 2019;54:507–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30406283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Freire de Carvalho J, Machado Ribeiro F. Sjögren syndrome associated with obsessive-compulsive disorder. Eur Rev Med Pharmacol Sci. 2020;24:11801–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33275251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cappi C, Brentani H, Lima L, Sanders SJ, Zai G, Diniz BJ, et al.  Whole-exome sequencing in obsessive-compulsive disorder identifies rare mutations in immunological and neurodevelopmental pathways. Transl Psychiatry. 2016;6:e764.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4872454</ArticleId>
            <ArticleId IdType="pubmed">27023170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez N, Morer A, González-Navarro EA, Gassó P, Boloc D, Serra-Pagès C, et al.  Human-leukocyte antigen class II genes in early-onset obsessive-compulsive disorder. World J Biol Psychiatry. 2019;20:352–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28562177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herdi O, Sayar-Akaslan D, İlhan RS, Çolak B, Duman B. Associations between subclinical inflammatory markers and OCD: a retrospective study. Psychiatry Res. 2020;290:113065.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32470720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turna J, Grosman Kaplan K, Anglin R, Patterson B, Soreni N, Bercik P, et al.  The gut microbiome and inflammation in obsessive-compulsive disorder patients compared to age- and sex-matched controls: a pilot study. Acta Psychiatr Scand. 2020;142:337–47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32307692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cosco TD, Pillinger T, Emam H, Solmi M, Budhdeo S, Matthew Prina A, et al.  Immune aberrations in obsessive-compulsive disorder: a systematic review and meta-analysis. Mol Neurobiol. 2019;56:4751–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30382535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gray SM, Bloch MH. Systematic review of proinflammatory cytokines in obsessive-compulsive disorder. Curr Psychiatry Rep. 2012;14:220–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3625952</ArticleId>
            <ArticleId IdType="pubmed">22477442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang C, Ma X, Qi S, Han G, Li Y, Liu Y, et al.  Association between TNF-α-238G/A gene polymorphism and OCD susceptibility: a meta-analysis. Medicine. 2018;97:e9769.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5805438</ArticleId>
            <ArticleId IdType="pubmed">29384866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pearlman DM, Vora HS, Marquis BG, Najjar S, Dudley LA. Anti-basal ganglia antibodies in primary obsessive-compulsive disorder: systematic review and meta-analysis. Br J Psychiatry. 2014;205:8–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24986387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sutterland AL, Fond G, Kuin A, Koeter MW, Lutter R, van Gool T, et al.  Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta-analysis. Acta Psychiatr Scand. 2015;132:161–79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25877655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ebrahimi Taj F, Noorbakhsh S, Ghavidel Darestani S, Shirazi E, Javadinia S, Group A. β-hemolytic Streptococcal infection in children and the resultant neuro-psychiatric disorder; a cross sectional study; Tehran, Iran. Basic Clin Neurosci. 2015;6:38–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4741265</ArticleId>
            <ArticleId IdType="pubmed">27504155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox CJ, Zuccolo AJ, Edwards EV, Mascaro-Blanco A, Alvarez K, Stoner J, et al.  Antineuronal antibodies in a heterogeneous group of youth and young adults with tics and obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 2015;25:76–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4340634</ArticleId>
            <ArticleId IdType="pubmed">25658702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicolini H, López Y, Genis-Mendoza AD, Manrique V, Lopez-Canovas L, Niubo E, et al.  Detection of anti-streptococcal, antienolase, and anti-neural antibodies in subjects with early-onset psychiatric disorders. Actas Esp Psiquiatr. 2015;43:35–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25812540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhattacharyya S, Khanna S, Chakrabarty K, Mahadevan A, Christopher R, Shankar SK. Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder. Neuropsychopharmacology. 2009;34:2489–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19675532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khanna S, Ravi V, Shenoy PK, Chandramuki A, Channabasavanna SM. Cerebrospinal fluid viral antibodies in obsessive-compulsive disorder in an Indian population. Biol Psychiatry. 1997;41:883–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9099415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bodner SM, Morshed SA, Peterson BS. The question of PANDAS in adults. Biol Psychiatry. 2001;49:807–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11331090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bechter K, Bindl A, Horn M, Schreiner V. [Therapy-resistant depression with fatigue. A case of presumed streptococcal-associated autoimmune disorder] Nervenarzt. 2007;78:340–1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17160540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greenberg BD, Murphy DL, Swedo SE. Symptom exacerbation of vocal tics and other symptoms associated with streptococcal pharyngitis in a patient with obsessive-compulsive disorder and tics. Am J Psychiatry. 1998;155:1459–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9766784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nave AH, Harmel P, Buchert R, Harms L. Altered cerebral glucose metabolism normalized in a patient with a pediatric autoimmune neuropsychiatric disorder after streptococcal infection (PANDAS)-like condition following treatment with plasmapheresis: a case report. BMC Neurol. 2018;18:60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5930772</ArticleId>
            <ArticleId IdType="pubmed">29720109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swedo SE, Leckman JF, Rose NR From research subgroup to clinical syndrome: modifying the PANDAS criteria to describe PANS (pediatric acute-onset neuropsychiatric syndrome) Pediatr Therapeut. 2012, 2:2. 10.4172/2161-0665.1000113.</Citation>
        </Reference>
        <Reference>
          <Citation>Kim Y, Ko TS, Yum MS, Jung AY, Kim HW. Obsessive-compulsive disorder related to mycoplasma-associated autoimmune encephalopathy with basal ganglia involvement. J Child Adolesc Psychopharmacol. 2016;26:400–2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26872247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson M, Fernell E, Preda I, Wallin L, Fasth A, Gillberg C, et al.  Paediatric acute-onset neuropsychiatric syndrome in children and adolescents: an observational cohort study. Lancet Child Adolesc Health. 2019;3:175–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30704875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sigra S, Hesselmark E, Bejerot S. Treatment of PANDAS and PANS: a systematic review. Neurosci Biobehav Rev. 2018;86:51–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29309797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muehlschlegel S, Okun MS, Foote KD, Coco D, Yachnis AT, Fernandez HH. Paraneoplastic chorea with leukoencephalopathy presenting with obsessive-compulsive and behavioral disorder. Mov Disord. 2005;20:1523–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16037914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al.  A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15:391–404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5066574</ArticleId>
            <ArticleId IdType="pubmed">26906964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herken J, Prüss H. Red flags: clinical signs for identifying autoimmune encephalitis in psychiatric patients. Front Psychiatry. 2017;8:25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5311041</ArticleId>
            <ArticleId IdType="pubmed">28261116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pollak TA, Lennox BR, Müller S, Benros ME, Prüss H, Tebartz van Elst L, et al.  Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. Lancet Psychiatry. 2020;7:93–108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31669058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lepri G, Rigante D, Bellando Randone S, Meini A, Ferrari A, Tarantino G, et al.  Clinical-serological characterization and treatment outcome of a large cohort of Italian children with pediatric autoimmune neuropsychiatric disorder associated with Streptococcal infection and pediatric acute neuropsychiatric syndrome. J Child Adolesc Psychopharmacol. 2019;29:608–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31140830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esposito S, Bianchini S, Baggi E, Fattizzo M, Rigante D. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: an overview. Eur J Clin Microbiol Infect Dis. 2014;33:2105–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24953744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frick LR, Rapanelli M, Jindachomthong K, Grant P, Leckman JF, Swedo S, et al.  Differential binding of antibodies in PANDAS patients to cholinergic interneurons in the striatum. Brain Behav Immun. 2018;69:304–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5857467</ArticleId>
            <ArticleId IdType="pubmed">29233751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brimberg L, Benhar I, Mascaro-Blanco A, Alvarez K, Lotan D, Winter C, et al.  Behavioral, pharmacological, and immunological abnormalities after streptococcal exposure: a novel rat model of Sydenham chorea and related neuropsychiatric disorders. Neuropsychopharmacology. 2012;37:2076–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3398718</ArticleId>
            <ArticleId IdType="pubmed">22534626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morris-Berry CM, Pollard M, Gao S, Thompson C, Singer HS, Tourette Syndrome Study Group.  Anti-streptococcal, tubulin, and dopamine receptor 2 antibodies in children with PANDAS and Tourette syndrome: single-point and longitudinal assessments. J Neuroimmunol. 2013;264:106–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24080310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chain JL, Alvarez K, Mascaro-Blanco A, Reim S, Bentley R, Hommer R, et al.  Autoantibody biomarkers for basal ganglia encephalitis in sydenham chorea and pediatric autoimmune neuropsychiatric disorder associated with Streptococcal infections. Front Psychiatry. 2020;11:564.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7328706</ArticleId>
            <ArticleId IdType="pubmed">32670106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kirvan CA, Swedo SE, Heuser JS, Cunningham MW. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nat Med. 2003;9:914–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12819778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalmau J, Geis C, Graus F. Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system. Physiol Rev. 2017;97:839–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5539405</ArticleId>
            <ArticleId IdType="pubmed">28298428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu J, Liu RJ, Fahey S, Frick L, Leckman J, Vaccarino F, et al.  Antibodies from children with PANDAS bind specifically to striatal cholinergic interneurons and alter their activity. Am J Psychiatry. 2020;16:appiajp202019070698–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8573771</ArticleId>
            <ArticleId IdType="pubmed">32539528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Platt MP, Agalliu D, Cutforth T. Hello from the other side: how autoantibodies circumvent the blood-brain barrier in autoimmune encephalitis. Front Immunol. 2017;21:8–442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5399040</ArticleId>
            <ArticleId IdType="pubmed">28484451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Platt MP, Bolding KA, Wayne CR, Chaudhry S, Cutforth T, Franks KM, et al.  Th17 lymphocytes drive vascular and neuronal deficits in a mouse model of postinfectious autoimmune encephalitis. Proc Natl Acad Sci USA. 2020;117:6708–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7104239</ArticleId>
            <ArticleId IdType="pubmed">32161123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dileepan T, Smith ED, Knowland D, Hsu M, Platt M, Bittner-Eddy P, et al.  Group A Streptococcus intranasal infection promotes CNS infiltration by streptococcal-specific Th17 cells. J Clin Invest. 2016;126:303–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4701547</ArticleId>
            <ArticleId IdType="pubmed">26657857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pisetsky DS, Lipsky PE. New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nat Rev Rheumatol. 2020;16:565–79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8456518</ArticleId>
            <ArticleId IdType="pubmed">32884126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barennes et al. Benchmarking of T cell receptor repertoire profiling methods reveals large systematic biases. Nat Biotechnol. 2020 Sep 7. 10.1038/s41587-020-0656-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32895550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharabi A, Tsokos MG, Ding Y, Malek TR, Klatzmann D, Tsokos GC. Regulatory T cells in the treatment of disease. Nat Rev Drug Discov. 2018;17:823–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30310234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol. 2015;15:283–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25882245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenzwajg M, Salet R, Lorenzon R, Tchitchek N, Roux A, Bernard C, et al.  Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study. Diabetologia. 2020;63:1808–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32607749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim JA, Lee ST, Moon J, Jun JS, Park BS, Byun JI, et al.  New feasible treatment for refractory autoimmune encephalitis: Low-dose interleukin-2. J Neuroimmunol. 2016;299:107–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27725107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prüss H. Postviral autoimmune encephalitis: manifestations in children and adults. Curr Opin Neurol. 2017;30:327–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28234798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prüss H, Finke C, Höltje M, Hofmann J, Klingbeil C, Probst C, et al.  N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. Ann Neurol. 2012;72:902–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3725636</ArticleId>
            <ArticleId IdType="pubmed">23280840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Armangue T, Spatola M, Vlagea A, Mattozzi S, Cárceles-Cordon M, Martinez-Heras E, et al.  Spanish Herpes Simplex Encephalitis Study Group. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol. 2018;17:760–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6128696</ArticleId>
            <ArticleId IdType="pubmed">30049614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tamouza R, Krishnamoorthy R, Leboyer M. Understanding the genetic contribution of the human leukocyte antigen system to common major psychiatric disorders in a world pandemic context. Brain Behav Immun. 2021;91:731–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7534661</ArticleId>
            <ArticleId IdType="pubmed">33031918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Donadi EA, Smith AG, Louzada-Júnior P, Voltarelli JC, Nepom GT. HLA class I and class II profiles of patients presenting with Sydenham’s chorea. J Neurol. 2000;247:122–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10751115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stanevicha V, Eglite J, Sochnevs A, Gardovska D, Zavadska D, Shantere R. HLA class II associations with rheumatic heart disease among clinically homogeneous patients in children in Latvia. Arthritis Res Ther. 2003;5:R340–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC333411</ArticleId>
            <ArticleId IdType="pubmed">14680508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costas J, Carrera N, Alonso P, Gurriarán X, Segalàs C, Real E, et al.  Exon-focused genome-wide association study of obsessive-compulsive disorder and shared polygenic risk with schizophrenia. Transl Psychiatry. 2016;6:e768.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4872458</ArticleId>
            <ArticleId IdType="pubmed">27023174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium.  Genome-wide association study identifies five new schizophrenia loci. Nat Genet. 2011;43:969–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3303194</ArticleId>
            <ArticleId IdType="pubmed">21926974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noble JA. Immunogenetics of type 1 diabetes: a comprehensive review. J Autoimmun. 2015;64:101–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26272854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reveille JD. The genetic contribution to the pathogenesis of rheumatoid arthritis. Curr Opin Rheumatol. 1998;10:187–200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9608321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holoshitz J. The rheumatoid arthritis HLA-DRB1 shared epitope. Curr Opin Rheumatol. 2010;22:293–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2921962</ArticleId>
            <ArticleId IdType="pubmed">20061955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Warren RP, Odell JD, Warren WL, Burger RA, Maciulis A, Daniels WW, et al.  Strong association of the third hypervariable region of HLA-DR beta 1 with autism. J Neuroimmunol. 1996;67:97–102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8765331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bedford SA, Hunsche MC, Kerns CM. Co-occurrence, assessment and treatment of obsessive compulsive disorder in children and adults with autism spectrum disorder. Curr Psychiatry Rep. 2020;22:53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32803413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kotb M, Norrby-Teglund A, McGeer A, Green K, Low DE. Association of human leukocyte antigen with outcomes of infectious diseases: the streptococcal experience. Scand J Infect Dis. 2003;35:665–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14620152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Endres D, Matysik M, Feige B, Venhoff N, Schweizer T, Michel M, et al.  Diagnosing organic causes of schizophrenia spectrum disorders: findings from a one-year cohort of the Freiburg diagnostic protocol in psychosis (FDPP) Diagnostics. 2020;10:691.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7555162</ArticleId>
            <ArticleId IdType="pubmed">32937787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Endres D, Leypoldt F, Bechter K, Hasan A, Steiner J, Domschke K, et al.  Autoimmune encephalitis as a differential diagnosis of schizophreniform psychosis: clinical symptomatology, pathophysiology, diagnostic approach, and therapeutic considerations. Eur Arch Psychiatry Clin Neurosci. 2020;270:803–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7474714</ArticleId>
            <ArticleId IdType="pubmed">32166503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perani D, Colombo C, Bressi S, Bonfanti A, Grassi F, Scarone S, et al.  [18F]FDG PET study in obsessive-compulsive disorder. A clinical/metabolic correlation study after treatment. Br J Psychiatry. 1995;166:244–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7728370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Attwells S, Setiawan E, Wilson AA, Rusjan PM, Mizrahi R, Miler L, et al.  Inflammation in the neurocircuitry of obsessive-compulsive disorder. JAMA Psychiatry. 2017;74:833–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5710556</ArticleId>
            <ArticleId IdType="pubmed">28636705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Endres D, Prüss H, Rauer S, Süß P, Venhoff N, Feige B, et al.  Probable autoimmune catatonia with antibodies against cilia on hippocampal granule cells and highly suspicious cerebral FDG-positron emission tomography findings. Biol Psychiatry. 2020;87:e29–e31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32122620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meyer JH, Cervenka S, Kim MJ, Kreisl WC, Henter ID, Innis RB. Neuroinflammation in psychiatric disorders: PET imaging and promising new targets. Lancet Psychiatry. 2020;7:1064–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7893630</ArticleId>
            <ArticleId IdType="pubmed">33098761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Connery K, Tippett M, Delhey LM, Rose S, Slattery JC, Kahler SG, et al.  Intravenous immunoglobulin for the treatment of autoimmune encephalopathy in children with autism. Transl Psychiatry. 2018;8:148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6086890</ArticleId>
            <ArticleId IdType="pubmed">30097568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frye RE, Shimasaki C. Reliability of the Cunningham panel. Transl Psychiatry. 2019;9:129.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6453973</ArticleId>
            <ArticleId IdType="pubmed">30962420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimasaki C, Frye RE, Trifiletti R, Cooperstock M, Kaplan G, Melamed I, et al.  Evaluation of the Cunningham Panel™ in pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS): changes in antineuronal antibody titers parallel changes in patient symptoms. J Neuroimmunol. 2020;339:577138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31884258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hesselmark E, Bejerot S. Biomarkers for diagnosis of Pediatric Acute Neuropsychiatric Syndrome (PANS) - sensitivity and specificity of the Cunningham Panel. J Neuroimmunol. 2017;312:31–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28919236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kreye J, Wenke NK, Chayka M, Leubner J, Murugan R, Maier N, et al.  Human cerebrospinal fluid monoclonal N-methyl-D-aspartate receptor autoantibodies are sufficient for encephalitis pathogenesis. Brain. 2016;139:2641–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27543972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jézéquel J, Rogemond V, Pollak T, Lepleux M, Jacobson L, Gréa H, et al.  Cell- and single molecule-based methods to detect anti-N-methyl-D-aspartate receptor autoantibodies in patients with first-episode psychosis from the OPTiMiSE project. Biol Psychiatry. 2017;82:766–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28780967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lennox BR, Palmer-Cooper EC, Pollak T, Hainsworth J, Marks J, Jacobson L, et al.  Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis: a case-control study. Lancet Psychiatry. 2017;4:42–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5890880</ArticleId>
            <ArticleId IdType="pubmed">27965002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Endres D, Meixensberger S, Dersch R, Feige B, Stich O, Venhoff N, et al.  Cerebrospinal fluid, antineuronal autoantibody, EEG, and MRI findings from 992 patients with schizophreniform and affective psychosis. Transl Psychiatry. 2020;10:279.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7419532</ArticleId>
            <ArticleId IdType="pubmed">32782247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giedd JN, Rapoport JL, Leonard HL, Richter D, Swedo SE. Case study: acute basal ganglia enlargement and obsessive-compulsive symptoms in an adolescent boy. J Am Acad Child Adolesc Psychiatry. 1996;35:913–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8768351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giedd JN, Rapoport JL, Garvey MA, Perlmutter S, Swedo SE. MRI assessment of children with obsessive-compulsive disorder or tics associated with streptococcal infection. Am J Psychiatry. 2000;157:281–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10671403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Endres D, Perlov E, Stich O, Rauer S, Maier S, Waldkircher Z, et al.  Hypoglutamatergic state is associated with reduced cerebral glucose metabolism in anti-NMDA receptor encephalitis: a case report. BMC Psychiatry. 2015;15:186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4522073</ArticleId>
            <ArticleId IdType="pubmed">26231521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirschtritt ME, Hammond CJ, Luckenbaugh D, Buhle J, Thurm AE, Casey BJ, et al.  Executive and attention functioning among children in the PANDAS subgroup. Child Neuropsychol. 2009;15:179–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2693234</ArticleId>
            <ArticleId IdType="pubmed">18622810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lewin AB, Storch EA, Mutch PJ, Murphy TK. Neurocognitive functioning in youth with pediatric autoimmune neuropsychiatric disorders associated with streptococcus. J Neuropsychiatry Clin Neurosci. 2011;23:391–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22231309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colvin MK, Erwin S, Alluri PR, Laffer A, Pasquariello K, Williams KA. Cognitive, graphomotor, and psychosocial challenges in pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) J Neuropsychiatry Clin Neurosci. 2020;2:appineuropsych20030065–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33261524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laplane D. [Obsessive-compulsive disorders caused by basal ganglia diseases] Rev Neurol. 1994;150:594–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7754296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Endres D, Perlov E, Riering AN, Maier V, Stich O, Dersch R, et al.  Steroid-responsive chronic schizophreniform syndrome in the context of mildly increased antithyroid peroxidase antibodies. Front Psychiatry. 2017;8:64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5399039</ArticleId>
            <ArticleId IdType="pubmed">28484400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leypoldt F, Buchert R, Kleiter I, Marienhagen J, Gelderblom M, Magnus T, et al.  Fluorodeoxyglucose positron emission tomography in anti-N-methyl-D-aspartate receptor encephalitis: distinct pattern of disease. J Neurol Neurosurg Psychiatry. 2012;83:681–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3740122</ArticleId>
            <ArticleId IdType="pubmed">22566598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baumgartner A, Rauer S, Mader I, Meyer PT. Cerebral FDG-PET and MRI findings in autoimmune limbic encephalitis: correlation with autoantibody types. J Neurol. 2013;260:2744–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23900756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deuschl C, Rüber T, Ernst L, Fendler WP, Kirchner J, Mönninghoff C, et al.  18F-FDG-PET/MRI in the diagnostic work-up of limbic encephalitis. PLoS ONE. 2020;15:e0227906.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6968877</ArticleId>
            <ArticleId IdType="pubmed">31951636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thienemann M, Murphy T, Leckman J, Shaw R, Williams K, Kapphahn C, et al.  Clinical management of pediatric acute-onset neuropsychiatric syndrome: part I-psychiatric and behavioral interventions. J Child Adolesc Psychopharmacol. 2017;27:566–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5610394</ArticleId>
            <ArticleId IdType="pubmed">28722481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frankovich J, Swedo S, Murphy T, Dale RC, Agalliu D, Williams K, et al. Clinical management of pediatric acute-onset neuropsychiatric syndrome: part II—use of immunomodulatory therapies. J Child Adolesc Psychopharmacol. 2017, 10.1089/cap.2016.0148..</Citation>
        </Reference>
        <Reference>
          <Citation>Cooperstock MS, Swedo SE, Pasternack MS, Murphy TK, PANS/PANDAS Consortium. Clinical management of pediatric acute-onset neuropsychiatric syndrome: Part III—Treatment and prevention of infections J Child Adolesc Psychopharmacol. 2017, 10.1089/cap.2016.0151..</Citation>
        </Reference>
        <Reference>
          <Citation>Swedo SE, Frankovich J, Murphy TK. Overview of treatment of pediatric acute-onset neuropsychiatric syndrome. J Child Adolesc Psychopharmacol. 2017;27:562–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5610386</ArticleId>
            <ArticleId IdType="pubmed">28722464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perlmutter SJ, Leitman SF, Garvey MA, Hamburger S, Feldman E, Leonard HL, et al.  Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet. 1999;354:1153–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10513708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williams KA, Swedo SE, Farmer CA, Grantz H, Grant PJ, D'Souza P, et al.  Randomized, controlled trial of intravenous immunoglobulin for pediatric autoimmune neuropsychiatric disorders associated with Streptococcal infections. J Am Acad Child Adolesc Psychiatry. 2016;55:860–.e2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27663941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy TK, Brennan EM, Johnco C, Parker-Athill EC, Miladinovic B, Storch EA, et al.  A double-blind randomized placebo-controlled pilot study of azithromycin in youth with acute-onset obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 2017;27:640–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28358599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Snider LA, Lougee L, Slattery M, Grant P, Swedo SE. Antibiotic prophylaxis with azithromycin or penicillin for childhood-onset neuropsychiatric disorders. Biol Psychiatry. 2005;57:788–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15820236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burchi E, Pallanti S. Antibiotics for PANDAS? Limited evidence: review and putative mechanisms of action. Prim Care Companion CNS Disord. 2018;20:17r02232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29722936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kreye J, Reincke SM, Kornau HC, Sánchez-Sendin E, Corman VM, Liu H, et al.  A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model. Cell. 2020;23:S0092-8674(20)31246-0–1069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7510528</ArticleId>
            <ArticleId IdType="pubmed">33058755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Endres D, Werden R, Schweizer T, Schröter N, Schiele MA, Nickel K, et al.  Novel neuronal autoantibodies in Huntington’s disease. Biol Psychiatry. 2021;12:S0006-3223(21)00043-3.</Citation>
        </Reference>
        <Reference>
          <Citation>Bejerot S, Hesselmark E. The Cunningham Panel is an unreliable biological measure. Transl Psychiatry. 2019;9:49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6355775</ArticleId>
            <ArticleId IdType="pubmed">30705260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bejerot S, Klang A, Hesselmark E. The Cunningham Panel: concerns remain. Transl Psychiatry. 2019;9:224.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6736884</ArticleId>
            <ArticleId IdType="pubmed">31506420</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
